Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

diffuse midline glioma, H3 K27-altered - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

diffuse midline glioma, H3 K27-altered

MONDO:1060171

Also known as:DMG, H3 K27-altered

Find Clinical TrialsTrials

Overview

A diffuse midline glioma characterized by H3 K27 alteration and usually either a histone H3 K27M mutation, an EGFR mutation, or aberrant overexpression of EZHIP. The prognosis is poor.

Clinical Trials3 registered · 1 recruiting

Diagnosis

Biomarker and diagnostic research for diffuse midline glioma, H3 K27-altered has been reported in the published literature.

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

3 clinical trials registered, 1 recruiting. Interventions under study include drug therapy, other interventions, medical devices, and procedural interventions. Pipeline includes 3 PHASE1. Research is primarily sponsored by academic and government institutions.

34 publications have been identified in PubMed for diffuse midline glioma, H3 K27-altered. Research spans Basic Science / Preclinical (29%), Case Report / Case Series (26%), and Review / Meta-Analysis (24%).

Research Type	Count	% of Total
Laboratory research	10

Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 4:02 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→Are any of the 3 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Kisho

diffuse midline glioma, H3 K27-altered

Overview

Diagnosis

Research Landscape

Medical References

Questions for Your Care Team

Questions for Your Care Team

Recent Publications

Latest News & Developments

Clinicopathological characterization and prognostic factors of H3 K27M-altered diffuse midline gliomas: A real-world cohort study.

Synergistic cell-cycle repression by HDAC/EZH2 co-targeting in H3K27-altered diffuse midline glioma.

Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clinical Trials with a Focus on Diffuse Midline Glioma.

diffuse midline glioma, H3 K27-altered

Overview

Diagnosis

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Recent Publications

Latest News & Developments

Clinicopathological characterization and prognostic factors of H3 K27M-altered diffuse midline gliomas: A real-world cohort study.

Synergistic cell-cycle repression by HDAC/EZH2 co-targeting in H3K27-altered diffuse midline glioma.

Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clinical Trials with a Focus on Diffuse Midline Glioma.